What is Glandokort?
Glandokort is described by its developer as a low-molecular-weight peptide complex extracted from adrenal tissue. It is a mixture of peptide fractions, rather than a molecule with one established amino-acid sequence.[1]
The adrenal association describes the material’s tissue origin and the developer’s intended target. It does not identify which ingredient acts on adrenal cells, or establish that the mixture supplies a defined amount of an adrenal hormone.[1]
Capsules and lingual drops are separate presentations. Capsule counts do not specify a drop concentration or demonstrate that the two forms deliver the same amount of active material.[1]
What Glandokort is investigated for
Glandokort evidence is grouped by practical use case and oral route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.
Adrenal function
Oral
Adrenal function
Oral
Restoration of adrenal hormone production remains unestablished. Glandokort cannot replace required hormone treatment.[6]
Human evidence
Human evidence for an independent improvement in adrenal function remains limited.
Animal / mechanistic evidence
The active mixture and a product-specific molecular target have not been independently established.[1]
Evidence snapshot
Overall confidence
Glandokort has a tissue-based rationale, with limited clinical support and uncertain active components.[1]
Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.
Human evidence
An independent clinical benefit remains unestablished.
Animal / preclinical
The mixture’s active ingredients and product-specific preclinical effects have not been independently characterized.[1]
Mechanism support
The proposed activity is attributed to adrenal-tissue peptide fractions. The mixture’s composition and molecular targets are not independently established.[1]
Forms & administration
Glandokort has oral capsules and lingual drops. Strength and delivered amount are product-specific; capsule counts cannot determine the amount in a drop formulation.[1][2]
Dosing & protocols
These ranges are general reference points, not personal dosing instructions.
Safety profile
Glandokort does not have an independently established safety profile. Adrenal insufficiency requires prescribed hormone replacement; an adrenal-derived peptide mixture is not a demonstrated substitute.[6]
Regulatory status
United States
Glandokort is not an FDA-approved drug name. Availability of a supplement or research preparation does not establish approval for a medical use.[3]
| Route | FDA drug approval | 503A compounding |
|---|---|---|
| Oral | Not Approved Glandokort is not an FDA-approved drug name. Availability of a supplement or research preparation does not establish approval for a medical use.[3] | Not Reviewed Compounding eligibility for this specific preparation has not been confirmed. Drug approval and compounding eligibility are separate questions. |
Oral
FDA drug approval
Not ApprovedGlandokort is not an FDA-approved drug name. Availability of a supplement or research preparation does not establish approval for a medical use.[3]
503A compounding
Not ReviewedCompounding eligibility for this specific preparation has not been confirmed. Drug approval and compounding eligibility are separate questions.
International
Medicinal-product authorization outside the United States remains unconfirmed for the named preparation; status depends on the exact product and country.[3]
Sports & competition
WADA S0 prohibits pharmacological substances without governmental approval for human therapeutic use when no later section addresses them. An unapproved peptide preparation is not athlete-cleared.
How it works
The proposed mechanism involves adrenal-derived peptide fractions influencing adrenal-cell activity. The active components and their molecular targets remain uncertain.[1]
Its tissue origin provides the rationale for adrenal support; it does not make the complex a defined adrenal-hormone replacement.
Research gaps & open questions
What the current literature has not yet settled about Glandokort:
Chemical characterization needs to identify the active ingredients and their amounts, so that different batches and capsule/drop products can be compared.[1]
Independent controlled trials need to measure adrenal hormone levels, symptoms and adverse effects alongside unchanged standard care. The developer evaluation cannot isolate a treatment effect.
Repeated-use and interaction studies need to establish safety with prescribed hormone replacement; the small combined-care report cannot quantify those risks.
Common questions
Is Glandokort a single peptide?
No. It is described as an adrenal-tissue peptide mixture, without one established active sequence.[1]
Are capsules and lingual drops equivalent?
Not established. They have separate presentations, and capsule counts do not define a matching concentration, absorbed amount or schedule for drops.[1]
History & discovery
Glandokort’s documented history is mainly a developer product and clinical-report history. A dated, independently characterized discovery of its active ingredients is not available.[1]
The report describes 36 participants receiving Glandokort and 26 usual-care controls. Allocation methods and independent replication are lacking, limiting what can be concluded about an added treatment effect.
A later developer proposal places Glandokort within a multi-peptide sequence. This is a proposed product schedule, rather than a trial establishing which ingredient improves adrenal function.[5]
6 citations
Glandokort research concerns adrenal function and adaptation to stress. Clinical evidence is limited, and the mixture’s active components and independent effects remain uncertain.[1][2][5]
